Investigational drug · Phase 2
RDE
Also called: ABSK141-Recommended Expansion, S095018 Recommended
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Solid Tumors, Adult, Non-small Cell Lung Cancer (NSCLC).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
140
Any phase or sponsor naming "RDE"
First trial start
2024
Aug 7, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RDE", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumors, Adult
- Non-small Cell Lung Cancer (NSCLC)
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "RDE" as an intervention, largest first.
Kestrel Therapeutics, Inc.Academic, hospital or other
NCT07458347 · 545 participants (planned) · Start Apr 21, 2026 · Primary completion Apr 2028
Drug: KST-6051; Gemcitabine/nab-paclitaxel and 6 more · For: KRAS-mutant Non-small Cell Lung Cancer (NSCLC); KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC); KRAS-mutant Colorectal Cancer (CRC) and 1 more
Sites: Los Angeles, California; Sarasota, Florida; Tampa, Florida · 9 sites in all
Abbisko Therapeutics Co, LtdIndustry
NCT07417189 · 401 participants (planned) · Start Mar 2, 2026 · Primary completion Dec 30, 2028
Drug: ABSK141-400mg; ABSK141-Recommended Dose for Expansion (RDE) and 3 more · For: Solid Tumors, Adult
Sites: Shanghai, China
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT07739966 · 400 participants (planned) · Start Oct 13, 2026 · Primary completion Jul 31, 2030
Drug: DS-3939a; Pembrolizumab and 3 more · For: Solid Tumor; Locally Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer
Sites: Fayetteville, Arkansas; Los Angeles, California; Tampa, Florida · 76 sites in all
ExelixisIndustry
NCT06545331 · 396 participants (planned) · Start Aug 6, 2024 · Primary completion Nov 23, 2026
Drug: XB010; Pembrolizumab · For: Locally Advanced or Metastatic Solid Tumors; Esophageal Squamous Cell Cancer; Head and Neck Squamous Cell Cancer and 3 more
Sites: Irvine, California; Los Angeles, California; Washington D.C., District of Columbia · 20 sites in all
MacroGenicsIndustry
NCT06242470 · 394 participants (planned) · Start Mar 6, 2024 · Primary completion Oct 2028
Drug: MGC026 Dose Escalation; MGC026 Dose for Expansion and 2 more · For: Advanced Solid Tumor; Advanced Cancer; Metastatic Cancer and 19 more
Sites: Los Angeles, California; Grand Rapids, Michigan; Lake Success, New York · 12 sites in all
Antares Therapeutics, IncIndustry
NCT07767474 · 343 participants (planned) · Start Aug 31, 2026 · Primary completion Oct 28, 2029
Drug: ATX-898; ATX-898 and 6 more · For: Advanced Solid Tumors
Sites: Fort Worth, Texas; Houston, Texas; San Antonio, Texas · 6 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT02081378 · 326 participants · Start Apr 24, 2014 · Primary completion Jun 3, 2021
Drug: Asciminib (ABL001); Nilotinib and 2 more · For: Chronic Myelogenous Leukemia; Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Sites: Boston, Massachusetts; Ann Arbor, Michigan; New York, New York · 18 sites in all
- U3-1402 in Metastatic or Unresectable Non-Small Cell Lung CancerActive, not recruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT03260491 · 312 participants · Start Oct 30, 2017 · Primary completion Dec 1, 2025
Drug: HER3-DXd (FL-DP); HER3-DXd (CTM-1 Lyo-DP) and 1 more · For: Non-Small Cell Lung Cancer (NSCLC)
Sites: Duarte, California; La Jolla, California; Long Beach, California · 37 sites in all
- Study of INCB123667 in Subjects With Advanced Solid TumorsActive, not recruiting
Incyte CorporationIncyte (INCY)
NCT05238922 · 291 participants · Start Jul 5, 2022 · Primary completion Jul 27, 2027
Drug: INCB0123667; Palbociclib and 5 more · For: Solid Tumors
Sites: Duarte, California; Irvine, California; Los Angeles, California · 41 sites in all
- A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid TumorsPivotal-lookingRecruiting
Vividion Therapeutics, Inc.Industry
NCT05954312 · 290 participants (planned) · Start Jul 28, 2023 · Primary completion Aug 31, 2030
Drug: VVD-130037; Docetaxel and 2 more · For: Advanced Solid Tumors
Sites: Jacksonville, Florida; Sarasota, Florida; Tampa, Florida · 26 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A concentration-source-driven and GPU-accelerated standalone radiochemistry framework for continuous water radiolysis and pulse-structure simulation.
Hu S, Huang JL, Wei Z, et al. · Phys Med Biol 2026
- Bridging Spectroscopy and Reactivity: Identifying the True Reactive CO Species in Electrocatalytic CO Oxidation.
Yang TY, Huang YJ, Geng HF, et al. · J Am Chem Soc 2026
- Ammonia emissions from range-extended electric vehicles under coupled temperature-HVAC conditions.
Wen Y, Ge Y, Tan J, et al. · J Hazard Mater 2026
- Mutational binding assessment for TCR engineering on experimental and AlphaFold 3 scaffolds.
Guo Z, Oyama K, Yamaguchi R · Front Bioinform 2026
- Practice-dependent changes in body representation but not in reaching distance following virtual tool-use.
Jahanian Najafabadi A, Kayser C · PLoS One 2026
- Interfacial Electrolyte Solution Reorganization as a Rate-Limiting Step for CO Adsorption on Pt in Electrochemical Environments.
Vuong HT, Watkins NB, Christopher P, et al. · J Am Chem Soc 2026
Also in development for Solid Tumors, Adult
- TersolisibLY4064809, STX-478Phase 33 trials
Eli Lilly · Breast Neoplasms, Neoplasm Metastasis, Breast Cancer
- ABSK141Phase 21 trial
Abbisko Therapeutics Co, Ltd · Solid Tumors, Adult
- TNG260Phase 21 trial
Tango Therapeutics, Inc. · Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.